English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17524/19853 (88%)
Visitors : 6472654      Online Users : 661
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/27640


    標題: A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer
    作者: Chen, Chin-Fan
    Huang, Ming-Yii
    Huang, Chih-Jen
    Wu, Chan-Han
    Yeh, Yung-Sung
    Tsai, Hsiang-Lin
    Ma, Cheng-Jen
    Lu, Chien-Yu
    Chang, Shun-Jen
    Chen, Ming-Jenn
    Wang, Jaw-Yuan
    貢獻者: 運動管理系
    關鍵字: Preoperative Chemoradiation
    Rectal Cancer
    Capecitabine
    5-Fu
    日期: 2012-06
    上傳時間: 2014-03-21 16:16:09 (UTC+8)
    出版者: Springer
    摘要: This study is to evaluate the safety and efficacy of preoperative radiotherapy (RT) combined with bolus infusional 5-fluorouracil (5-FU) or oral capecitabine in patients with locally advanced rectal cancer (LARC).Seventy-four patients were retrospectively analyzed. Twenty-seven patients were treated with 5-FU (350 mg/m(2) IV bolus) and leucovorin (20 mg/m(2) IV bolus) for 5 days/week during week 1 and 5 of RT. Forty-seven patients were treated with capecitabine (850 mg/m(2), twice daily for 5 days/week). Both groups received the same RT course (45-50.4 Gy/25 fractions, 5 days/week, for 5 weeks). Patients underwent surgery in 6 weeks after completion of the chemoradiotherapy. Data of the observational study were collected.Grade 3 or 4 toxicities occurred in 40.7% (5-FU) and 19.1% (capecitabine) of the patients (P = 0.044). Six patients in the 5-FU group (22.2%) and six patients in the capecitabine group (14%) achieved complete response. Primary tumor (T) downstaging were achieved in 51.9% (5-FU) and 69.8% (capecitabine) of the patients. The pathological ypT0-2 stage was 40.7% (5-FU) and 67.4% (capecitabine) (P = 0.028).In consideration of the better ypT0-2 downstaging rate, less severe toxicities, and no need for indwelling intravenous device on oral capecitabine regimen, the administration of oral capecitabine with RT may be a more favorable option in the neoadjuvant treatment for LARC.
    關聯: International Journal of Colorectal Disease, 27(6), 727-736
    Appears in Collections:[運動管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML623View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback